All New ESRD IV Drugs Should Get Break From Medicare Payment Bundle – Amgen
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS should not limit proposed transitional payments for IV and injectable ESRD drugs based on the current criteria for bundling, Amgen says. Company's approach could benefit its new IV caclimimetic drug candidate.
You may also be interested in...
Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market
Amgen's oral calcimimetic Sensipar faces generic competition in 2018, but the new intravenuous Parsabiv has advantages that could make it the more popular alternative.
Paying For Gene Therapy: Biggest Cost Challenges Two To Three Years Away?
Only about one-quarter of the 40 gene therapies projected to launch by the end of 2025 would have potential US patient populations of more than 50,000. But a handful of treatments could target millions of individuals.
340B Hospitals Charging Private Insurers Nearly Four Times Acquisition Costs On Cancer Drugs – Study
New report makes a case for further scrutiny of the 340B program's contributions to high drug costs, although manufacturers remain the main target of legislative and regulatory reform proposals.